PSEN1 and acute lymphoblastic leukemia: This is not the case for the selective PSEN1 inhibitor MRK-560, that demonstrated inhibition of mutant NOTCH1 processing and a decrease in the leukemia burden without causing gastrointestinal toxicity in T-ALL PDX in vivo.